

Supplementary Material 27 Cost effectiveness scenario analysis – exponential 40% decay in efficacy per annum

| | Costs | QALYs | ICER | Incremental net health benefit (95% CI) | | |
|-----------------------|--|---|-------------|--|-------------------------------------|-------------------------------------|
| | (95% CI) | (95% CI) | | k=£15,000 | k=£20,000 | k=£30,000 |
| | [P(most costly)] | [P(most effective)] | | [Probability of being cost-effective] | | |
| Control | £642.06 (507.14, 798.4) [0.085] | 17.79359 (17.77337, 17.81535) [0.059] | | - - [0.108] | - - [0.095] | - - [0.078] |
| SWAL only | £691.19 (563.3, 846.93) [0.216] | 17.80520 (17.78443, 17.82509) [0.285] | £4,231.15 | 0.008 (-0.018, 0.034) [0.359] | 0.009 (-0.016, 0.033) [0.336] | 0.01 (-0.013, 0.034) [0.318] |
| SWAL plus desk | £747.60 (641.42, 868.39) [0.699] | 17.81197 (17.79219, 17.8296) [0.656] | £8,329.87 | 0.011 (-0.02, 0.045) [0.533] | 0.013 (-0.017, 0.045) [0.569] | 0.015 (-0.016, 0.046) [0.604] |